SPORE Study Provides New Guidelines for Tamoxifen Use
Approximately half a million women in the United States alone currently take the drug tamoxifen, either as an adjuvant therapy for preinvasive or invasive breast cancer, or as a chemopreventive agent for those at high risk of the disease.
Now, a new study led by Dr. Matthew Goetz, an investigator for the Breast Cancer Specialized Program of Research Excellence (SPORE) at the Mayo Clinic, has shown that up to 10 percent of women taking the drug may not receive the intended benefit due to genetic differences in the way tamoxifen is metabolized. Additionally, a larger percentage of women may be at increased risk of treatment failure because of drug interactions. Read more
The Power of Numbers: Melding Genomics and Epidemiology
NCI is moving on a number of fronts to harness the power of new genomic technology through epidemiologic studies designed to uncover gene variants that contribute to cancer susceptibility. Findings from NCI's portfolio of family studies have formed the basis for our understanding of many high-penetrant cancer-causing mutations. These rare mutations give unprecedented insights into carcinogenic mechanisms, but are responsible for only a small proportion of all cancer. Most cancer risk is believed to be due to gene-environment interactions involving low-penetrant but common genetic variants or single nucleotide polymorphisms (SNPs). Read more